Search results for "Opportunistic screening"

showing 3 items of 3 documents

PCA3 as a second-line biomarker in a prospective controlled randomized opportunistic prostate cancer screening programme

2017

Objectives: PCA3 performance as a single second line biomarker is compared to the European Randomised Study of Screening for Prostate Cancer risk calculator model 3 (ERSPC RC-3) in an opportunistic screening in prostate cancer (PCa). Material and methods: 5,199 men, aged 40-75y, underwent prostate-specific antigen (PSA) screening and digital rectal examination (DRE). Men with a normal DRE and PSA >= 3 ng/ml had a PCA3 test done. All men with PCA3 >= 35 underwent an initial biopsy (IBx) 12 cores. Men with PCA3 = 3 ng/ml and DRE is normal, IBx could be avoided in 12.5% less than if ERSPC RC-3 is used and would reduce the false negative cases by 36.2%. At a FU of 21.7 months, this dual protoco…

AdultMalePCA3medicine.medical_specialty030232 urology & nephrologyUrologyurologic and male genital diseaseslaw.inventionOpportunistic screening03 medical and health sciencesProstate cancerPSA0302 clinical medicineSecond lineRandomized controlled trialAntigens NeoplasmlawBiopsyBiomarkers TumormedicineHumansProspective StudiesEarly Detection of CancerAgedGynecologyProstate cancermedicine.diagnostic_testbusiness.industryProstatic NeoplasmsGeneral MedicineRectal examinationMiddle Agedmedicine.diseaseProstate cancer screening030220 oncology & carcinogenesisBiomarker (medicine)PCA3business
researchProduct

Optimizing the clinical utility of PCA3 to diagnose prostate cancer in initial prostate biopsy.

2015

Background: PCA3 has been included in a nomogram outperforming previous clinical models for the prediction of any prostate cancer (PCa) and high grade PCa (HGPCa) at the initial prostate biopsy (IBx). Our objective is to validate such IBx-specific PCA3-based nomogram. We also aim to optimize the use of this nomogram in clinical practice through the definition of risk groups. Methods: Independent external validation. Clinical and biopsy data from a contemporary cohort of 401 men with the same inclusion criteria to those used to build up the reference’s nomogram in IBx. The predictive value of the nomogram was assessed by means of calibration curves and discrimination ability through the area…

PCA3MaleCancer Researchmedicine.medical_specialtyProstate biopsyBiopsyUrologyurologic and male genital diseasesRisk AssessmentDecision Support TechniquesCohort StudiesProstate cancerRisk groupsAntigens NeoplasmRisk FactorsGeneticsBiomarkers TumorMedicineHumansOpportunistic screeningAgedmedicine.diagnostic_testbusiness.industryArea under the curveExternal validationProstatic NeoplasmsOrgan SizeNomogramMiddle Agedmedicine.diseaseSurgeryNomogramsOncologybusinessBiomarkersResearch ArticleBMC cancer
researchProduct

Do we know more about hypertension in Poland after the May Measurement Month 2017?—Europe

2019

Abstract Elevated blood pressure (BP) is a worldwide burden, leading to over 10 million deaths yearly. May Measurement Month (MMM) is a global initiative organized by the International Society of Hypertension aimed at raising awareness of hypertension and the need for BP screening. An opportunistic cross-sectional survey of volunteers aged ≥18 was carried out in May 2017. BP measurement, the definition of hypertension and statistical analysis followed the globally approved MMM17 Study Protocol. In Poland 5834 (98.9%, Caucasian) individuals were screened. After multiple imputation, 2601 (35.3%) had hypertension. Of individuals not receiving anti-hypertensive medication, 976 (20.6%) were hype…

medicine.medical_specialtybusiness.industryArticles030204 cardiovascular system & hematologyOverweightmedicine.diseaseObesityElevated blood03 medical and health sciences0302 clinical medicineBlood pressureCardiovascular System & HematologyInternal medicinemedicineStatistical analysis030212 general & internal medicineSystoleUnderweightmedicine.symptomCardiology and Cardiovascular Medicinebusiness1102 Cardiorespiratory Medicine and HaematologyOpportunistic screeningEuropean Heart Journal Supplements
researchProduct